Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Axcella Health Inc | AXLA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 4.58 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.58 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.5875 - 41.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.58 | USD |
Axcella Health Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 13.5M | 2.95M | - | 0 | -81.19M | -27.54 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Axcella Health News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXLA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.55 | 5.60 | 4.55 | 4.63 | 19,845 | -0.97 | -17.48% |
| 1 Month | 5.42 | 6.75 | 4.07 | 5.28 | 30,779 | -0.84 | -15.5% |
| 3 Months | 9.445 | 41.25 | 4.07 | 22.32 | 10,581,618 | -4.87 | -51.51% |
| 6 Months | 10.0425 | 41.25 | 2.5875 | 15.78 | 10,326,865 | -5.46 | -54.39% |
| 1 Year | 28.00 | 41.25 | 2.5875 | 15.63 | 5,533,879 | -23.42 | -83.64% |
| 3 Years | 143.50 | 171.00 | 2.5875 | 18.70 | 1,927,673 | -138.92 | -96.81% |
| 5 Years | 378.00 | 398.50 | 2.5875 | 22.70 | 1,302,062 | -373.42 | -98.79% |
Axcella Health Description
| Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis. |
